Lung Cancer Drug Combo Extends Progression-Free Survival
Adults with PD-L1-negative lung cancer saw longer disease control with sac-TMT plus Keytruda, though survival benefit is still unknown.
Updated on Nov. 5, 2026 in Cancer
A phase 3 trial in China found that sacituzumab tirumotecan (sac-TMT) plus Keytruda extended progression-free survival compared with chemotherapy plus Keytruda in adults with previously untreated, PD-L1-negative nonsquamous non-small cell lung cancer. The findings were published October 25, 2026, in the New England Journal of Medicine, and overall survival data remain immature.
Why it matters
Many patients with PD-L1-negative tumors may benefit less from immunotherapy alone, so the trial tested whether swapping chemotherapy for sac-TMT could improve control of the disease. The results point to a possible new option in a group that has had fewer effective choices.
This randomized phase 3 trial enrolled 455 patients with PD-L1-negative, nonsquamous non-small cell lung cancer lacking targetable genomic alterations, comparing sac-TMT plus Keytruda against chemotherapy plus Keytruda. Sac-TMT plus Keytruda produced a median progression-free survival of 15 months versus 5.7 months, a 51% reduction in relative risk, but overall survival data remain immature at a median follow-up of 9.7 months.
The players
Keytruda (pembrolizumab)
An immunotherapy drug widely used in lung and other cancers that helps the immune system recognize and attack tumor cells.
New England Journal of Medicine
A leading peer-reviewed medical journal that published the trial results.
The details
Sac-TMT is an antibody-drug conjugate, a therapy that links a cancer-fighting medication to an antibody designed to deliver it to cells expressing the protein TROP2. In the trial, patients were randomized to receive either sac-TMT plus Keytruda or chemotherapy plus Keytruda, with Keytruda (pembrolizumab) serving as the immunotherapy backbone in both arms. Grade 3 or higher treatment-emergent adverse events occurred in 47.6% of patients receiving sac-TMT plus Keytruda, and stomatitis (mouth inflammation) was reported in 51.1%.
Timeline
The study was published in the New England Journal of Medicine on October 25, 2026.
Progression-free survival outcomes were measured at a median follow-up of 9.7 months.
Health Landscape
For patients with PD-L1-negative non-small cell lung cancer, the current standard has relied heavily on chemotherapy, and immunotherapy alone has offered limited benefit in this group. Antibody-drug conjugates targeting TROP2 are an emerging class being tested alongside immunotherapy to address this gap, though sac-TMT remains investigational in this setting in the United States.
If you have been diagnosed with PD-L1-negative lung cancer, this research is worth raising with your oncologist as an emerging option being studied alongside immunotherapy. Because the trial has not yet shown an overall survival benefit and carries notable side effects such as stomatitis, any decision about pursuing investigational treatment belongs in a conversation with your physician.
The takeaway
The trial suggests that antibody-drug conjugates may give PD-L1-negative lung cancer patients a meaningful progression benefit, but longer follow-up is needed before any survival advantage can be claimed. Patients interested in emerging options can ask their oncologist whether clinical trials are a suitable path.
Further reading
For broader context on treatment approaches, see our coverage in the Cancer section.
